首頁 > 市場調查報告書 > 製藥

市場調查報告書

商品編碼

1057217

甲狀腺眼症治療的全球市場:各診斷、各治療、各地區趨勢分析，競爭市場佔有率，預測(2021年～2027年)

Global Thyroid Eye Disease Market, By Diagnosis ; By Treatment ; By Region Trend Analysis, Competitive Market Share & Forecast, 2021-2027

出版日期: 2021年11月11日 | 出版商:

Blueweave Consulting & Research Private Limited | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

全貌
簡介
目錄

簡介

全球甲狀腺眼症治療的市場規模，2020年達到了2億3,760萬美元。預計2027年達到4億1,740萬美元，今後市場在預測期間內預計以9.1％的年複合成長率成長。

甲狀腺眼症的盛行率的上升，和該疾病治療的有利償付政策，成為市場成長的主要原因。

本報告提供全球甲狀腺眼症治療市場的相關調查，提供產業考察，市場概要，市場分析，企業簡介等全面性資訊。

市場規模與預測:各金額(2017年～2027年)
- 各金額(100萬美元)
市場佔有率與預測
- 各診斷
  - 超音波
  - 影像檢查
  - 放射性碘拿進來
  - 血液樣品
- 各治療
  - 抗甲狀腺藥
  - 放射性碘療法
  - 手術
- 各地區
  - 北美
  - 歐洲
  - 亞太地區
  - 南美
  - 中東和非洲

第6章北美的甲狀腺眼症治療市場

第7章歐洲的甲狀腺眼症治療市場

第8章亞太地區的甲狀腺眼症治療市場

第9章南美的甲狀腺眼症治療市場

第10章中東及非洲的甲狀腺眼症治療市場

第11章競爭情形

主要企業提供的清單
市場佔有率分析(2020年)
競爭基準:各行動參數

第12章 COVID-19對全球甲狀腺眼症治療市場的影響

第13章企業簡介概要(企業概要，財務矩陣，主要的治療形勢，主要的人員，主要的其他競爭公司，聯絡原住所，及策略性展望)*

Abbvie Inc.
Abbott Laboratories Inc.
Allergan Plc
Apitope Technology Ltd.
AstraZeneca Plc
Bristol-Myers Squibb Company
Eli Lilly and Company
Epivax, Inc
GlaxoSmithKline Plc
Johnson & Johnson
Macleods Pharmaceuticals Ltd.
Merck & Co., Inc
Mylan NV
Novartis International Ag
Pfizer Inc.
其他

Product Code: BWC19439

Global Thyroid Eye Disease Market Thriving -Projected to Accelerate at a CAGR of 9.1% by 2027

Global Thyroid Eye Disease market is anticipated to grow due to the steep rise in smoking habits has become the other key factor influencing the growth of the market. Fast food consumption has reduced dietary intake of nutritious foods, increasing the need for diagnosis and treatment, thereby impacting the global Thyroid eye disease market….

A study, recently conducted by the strategic consulting and market research firm BlueWeave Consulting, revealed that the global thyroid eye disease market was valued USD 237.6 million in 2020 and is further projected to reach USD 417.4 million by 2027, at a CAGR of 9.1% during the forecast period (2021-2027). The increasing prevalence of thyroid eye disease and favorable reimbursement policies for the treatment of the same are the key factors driving market growth. Additionally, the consumption of fast food or carbonated sodas and drinks has been the other major factors exacerbating the situation of hyperthyroidism patients.

Increasing Approval of Drugs for the Treatment of Thyroid Eye Disease

In January 2020, the Food and Drug Administration (FDA) approved teprotumumab-trbw (Tepezza, Horizon Therapeutics), which is considered the first medicine approved for the treatment of thyroid eye disease. Before the approval of teprotumumab-trbw, patients suffering from thyroid eye disease had to wait for approximately three years or more for their condition to go from acute phase to chronic phase for a series of surgeries to help restore vision and appearance of their eyes. At week 24, 82.9% of patients treated with teprotumumab-trbw had a 2-mm reduction in proptosis, compared to 9.5% of patients treated with placebo, with no deterioration in the other eye in the Tepezza phase 3 clinical trial. In Addition, according to FDA, 67.9% of patients treated with teprotumumab-trbw had at least 1-grade baseline change in diplopia at week 24 compared with 28.6% of patients treated with placebo. Thus, teprotumumab-trbw has changed the way doctors treat patients suffering from thyroid eye disease. Doctors now have a dedicated medicine that addresses the disease's primary causes, potentially reversing the disease's progression. Thus, the market for thyroid eye disease is growing due to increased technical breakthroughs and medicinal approvals.

Anti-Thyroid Medication Segment to Witness the Largest Growth in the Treatment Segment

Based on treatments, the global thyroid eye disease market is trisected into anti- thyroid medication, radioactive iodine therapy, and surgery. The anti-thyroid medication segment accounted for the largest share in the market in 2020 and is anticipated to record an impressive CAGR over the forecast period. Anti-thyroid medicines are the simplest way to treat this disease and has few to no adverse effects. Furthermore, methimazole (MMI) and propylthiouracil (PTU) are commonly utilized medications in the treatment. The disease is self-limited; however, if unchecked, inflammation of the eye tissues can cause permanent scars. Ocular lubricants may be sufficient in the early stages of the disease. However, the disease's increasing severity may necessitate adjustments in treatment and even hospitalization.

Impact of COVID-19 on Global Thyroid Eye Disease Market

The COVID-19 outbreak has negatively influenced the global Thyroid eye diseases market. Due to lockdown and travel restrictions, patients were unable to travel to hospitals, which reduced the demand for checkups. A study published in the Asia-Pacific Journal of Ophthalmology reported that ophthalmology centers are at the highest risk of transmitting COVID-19, which calls for extra precautionary measures. Close contact, aerosols, droplets, and others are the most common routes for the transfer of COVID-19. Thus, ophthalmologist centers are at the highest risk of infection due to exposure to these viral particles. In typical face-to-face ocular clinical examinations the slit lamp or direct ophthalmoscope is used in close proximity to the patient, thereby increasing the chances of contracting the coronavirus. Moreover numerous hospitals and clinics were used for treating COVID-19 patients, which resulted in delays in treatment and surgery.

Global Thyroid eye disease Market: Regional Insights

The global thyroid eye disease market is grouped into North America, Europe, the Asia-Pacific, Latin America and the Middle East and Africa. North America accounted for the largest share in the market in 2020. On the other hand, Europe accounted for the second-largest share in the market due to increasing smoking habits across the region. Smoking habits are commonly observed in Eastern Europe, which is heavily influenced by the substance. Because smoking is one of the major causes of the disease's spread, it opens up new prospects for the detection and treatment of thyroid eye disease

Competitive Landscape

The leading players in the global thyroid eye disease market are Pfizer Inc., Abbott Laboratories Inc., Abbvie Inc., Merck & Co., Inc., Horizon Therapeutics Plc, Johnson & Johnson, GE Healthcare, Carl Zeiss Meditec AG, Alcon Vision LLC, Eli Lilly and Company, Optovue Inc., RC Labs Inc., Hitachi Medical Systems America Inc., Kala Pharmaceuticals, Inc., Akron Pharmaceuticals, Carestream, Santen Pharmaceutical Co., Ltd., Fresnel Prism & Lens Co., TOMTEC Imaging Systems GmbH, and other prominent players. Due to a lack of understanding of the disease, thyroid eye disease has gone undiagnosed in a number of poor countries. Due to the rising awareness programs, the disease is becoming more recognized, resulting in the market's growth. As a result, the global thyroid eye disease market is becoming more concentrated.

Don't miss the business opportunity of the global thyroid eye disease market. Consult our analysts to gain crucial insights and facilitate your business growth.

The in-depth analysis of the report provides information about growth potential, upcoming trends, and statistics of the global thyroid eye disease market. It also highlights the factors driving forecasts of total market size. The report promises to provide recent technology trends in the ¬¬¬thyroid eye disease market, along with industry insights to help decision-makers make sound strategic decisions. Furthermore, the report also analyzes the growth drivers, challenges, and competitive dynamics of the market.

About Us

BlueWeave Consulting provides all-inclusive Market Intelligence (MI) Solutions to businesses regarding various products and services online & offline. We offer comprehensive market research reports by analyzing both qualitative and quantitative data to boost up the performance of your business solution. BWC has built its reputation from the scratches by delivering quality inputs and nourishing long-lasting relationships with its clients. We are one of the promising digital MI solutions companies providing agile assistance to make your business endeavors successful.

1. Research Framework

1.1. Research Objective
1.2. Product Overview
1.3. Market Segmentation

2. Research Methodology

2.1. Qualitative Research
- 2.1.1. Primary and Secondary Sources
2.2. Quantitative Research
- 2.2.1. Primary and Secondary Sources
2.3. Breakdown of Primary Research Respondents
- 2.3.1. Secondary Research
- 2.3.2. Primary Research
2.4. Breakdown of Primary Research Respondents, By Industry Participants
2.5. Market Breakdown & Data Triangulation

3. Executive Summary

4. Global Thyroid Eye Disease Market - Industry Insights

4.1. Value Chain Analysis
4.2. DROC Analysis
- 4.2.1. Growth Drivers
- 4.2.2. Restraints
- 4.2.3. Opportunity
- 4.2.4. Challenges
4.3. Recent Developments
4.4. Regulatory Framework
4.5. Porter Five Forces Analysis

5. Global Thyroid Eye Disease Market Overview

5.1. Market Size & Forecast by Value, 2017-2027
- 5.1.1. By Value (USD Million)
5.2. Market Share & Forecast
- 5.2.1. By Diagnosis
  - 5.2.1.1. Ultrasound
  - 5.2.1.2. Imaging Test
  - 5.2.1.3. Radioactive Iodine Uptake
  - 5.2.1.4. Blood Sample
- 5.2.2. By Treatment
  - 5.2.2.1. Anti- Thyroid Medication
  - 5.2.2.2. Radioactive Iodine Therapy
  - 5.2.2.3. Surgery
- 5.2.3. By Region
  - 5.2.3.1. North America
  - 5.2.3.2. Europe
  - 5.2.3.3. The Asia-Pacific
  - 5.2.3.4. Latin America
  - 5.2.3.5. The Middle East & Africa

6. North America Thyroid Eye Disease Market

6.1. Market Size & Forecast by Value, 2017-2027
- 6.1.1. By Value (USD Million)
6.2. Market Share & Forecast
- 6.2.1. By Diagnosis
- 6.2.2. By Treatment
- 6.2.3. By Country
  - 6.2.3.1. United States
  - 6.2.3.2. Canada

7. Europe Thyroid Eye Disease Market

7.1. Market Size & Forecast by Value, 2017-2027
- 7.1.1. By Value (USD Million)
7.2. Market Share & Forecast
- 7.2.1. By Diagnosis
- 7.2.2. By Treatment
- 7.2.3. By Country
  - 7.2.3.1. Germany
  - 7.2.3.2. United Kingdom
  - 7.2.3.3. France
  - 7.2.3.4. Italy
  - 7.2.3.5. Spain
  - 7.2.3.6. Russia
  - 7.2.3.7. Rest of Europe

8. Asia Pacific Thyroid Eye Disease Market

8.1. Market Size & Forecast by Value, 2017-2027
- 8.1.1. By Value (USD Million)
8.2. Market Share & Forecast
- 8.2.1. By Diagnosis
- 8.2.2. By Treatment
- 8.2.3. By Country
  - 8.2.3.1. China
  - 8.2.3.2. India
  - 8.2.3.3. Japan
  - 8.2.3.4. South Korea
  - 8.2.3.5. Singapore
  - 8.2.3.6. Rest of Asia Pacific

9. Latin America Thyroid Eye Disease Market

9.1. Market Size & Forecast by Value, 2017-2027
- 9.1.1. By Value (USD Million)
9.2. Market Share & Forecast
- 9.2.1. By Diagnosis
- 9.2.2. By Treatment
- 9.2.3. By Country
  - 9.2.3.1. Brazil
  - 9.2.3.2. Mexico
  - 9.2.3.3. Argentina
  - 9.2.3.4. Rest of Latin America

10.Middle East & Africa Thyroid Eye Disease Market

10.1. Market Size & Forecast by Value, 2017-2027
- 10.1.1. By Value (USD Million)
10.2. Market Share & Forecast
- 10.2.1. By Diagnosis
- 10.2.2. By Treatment
- 10.2.3. By Country
  - 10.2.3.1. Saudi Arabia
  - 10.2.3.2. UAE
  - 10.2.3.3. South Africa
  - 10.2.3.4. Rest of Middle East & Africa

11.Competitive Landscape

11.1. List of Key Players and Their Offerings
11.2. Market Share Analysis (2020)
11.3. Competitive Benchmarking, By Operating Parameters

12.Impact of COVID-19 on Global Thyroid Eye Disease Market

13.Company Profiles (Company Overview, Financial Matrix, Key Treatment landscape, Key Personnel, Key Competitors, Contact Address, and Strategic Outlook) *

13.1. Abbvie Inc.
13.2. Abbott Laboratories Inc.
13.3. Allergan Plc
13.4. Apitope Technology Ltd.
13.5. AstraZeneca Plc
13.6. Bristol-Myers Squibb Company
13.7. Eli Lilly and Company
13.8. Epivax, Inc
13.9. GlaxoSmithKline Plc
13.10. Johnson & Johnson
13.11. Macleods Pharmaceuticals Ltd.
13.12. Merck & Co., Inc
13.13. Mylan NV
13.14. Novartis International Ag
13.15. Pfizer Inc.
13.16. Other Prominent Players

List of Tables

Table 1: Global Thyroid Eye Disease Market Size (USD Million), By Diagnosis, By Value, 2017-2027
Table 2: Global Thyroid Eye Disease Market Size (USD Million), By Treatment, By Value, 2017-2027
Table 3: Global Thyroid Eye Disease Market Size. By Region, By Value (USD Million), 2017-2027
Table 4: North America Thyroid Eye Disease Market Size (USD Million), By Diagnosis, By Value, 2017-2027
Table 5: North America Thyroid Eye Disease Market Size (USD Million), By Treatment, By Value, 2017-2027
Table 6: North America Thyroid Eye Disease Market Size (USD Million), By Country, By Value 2017-2027
Table 7: Europe Thyroid Eye Disease Market Size (USD Million), By Diagnosis, By Value, 2017-2027
Table 8: Europe Thyroid Eye Disease Market Size (USD Million), By Treatment, By Value, 2017-2027
Table 9: Europe Thyroid Eye Disease Market Size (USD Million), By Country, By Value, 2017-2027
Table 10: The Asia-Pacific Thyroid Eye Disease Market Size (USD Million), By Diagnosis, By Value, 2017-2027
Table 11: The Asia-Pacific Thyroid Eye Disease Market Size (USD Million), By Treatment, By Value, 2017-2027
Table 12: The Asia-Pacific Thyroid Eye Disease Market Size (USD Million), By Country, By Value, 2017-2027
Table 13: Latin America Thyroid Eye Disease Market Size (USD Million), By Diagnosis, By Value, 2017-2027
Table 14: Latin America Thyroid Eye Disease Market Size (USD Million), By Treatment, By Value, 2017-2027
Table 15: Latin America Thyroid Eye Disease Market Size (USD Million), By Country, By Value, 2017-2027
Table 16: The Middle East & Africa Thyroid Eye Disease Market Size (USD Million), By Diagnosis, By Value, 2017-2027
Table 17: The Middle East & Africa Thyroid Eye Disease Market Size (USD Million), By Treatment, By Value, 2017-2027
Table 18: The Middle East & Africa Thyroid Eye Disease Market Size (USD Million), By Country, By Value, 2017-2027
Table 19: List of Key Players and Their Offerings
Table 20 : Competitive Benchmarking, by Operating Parameters
Table 21 Pfizer Inc. Overview
Table 22 : Pfizer Inc. Financial Analysis (USD Million)
Table 23 : Abbott Laboratories Overview
Table 24 : Abbott Financial Analysis (USD Million)
Table 25: Eli Lilly and Company Overview
Table 26: Eli Lilly and Company Financial Analysis (USD Million)
Table 27 : Abbvie Inc. Overview
Table 28 : Abbvie Inc. Financial Analysis (USD Million)
Table 29: Horizon Therapeutic Plc Overview
Table 30: Horizon Therapeutic Plc Financial Analysis (USD Million)
Table 31: RLC Labs Inc. Overview
Table 32: Alcon Vision LLC Overview
Table 33: Alcon Vision LLC Financial Analysis (USD Million)
Table 34: Carl Zeiss Meditec AG Overview
Table 35: Carl Zeiss Meditec AG Financial Analysis (USD Million)
Table 36: Johnson & Johnson Vision Overview
Table 37: Johnson & Johnson Vision Financial Analysis (USD Million)
Table 38: Akron Pharmaceuticals Overview
Table 39: Kala Pharmaceuticals, Inc. Overview
Table 40: Kala Pharmaceuticals, Inc. Financial Analysis (USD Million)
Table 41: Santen Pharmaceutical Co., Ltd. Overview
Table 42: Santen Pharmaceutical Co., Ltd. Financial Analysis (USD Million)
Table 43: Merck & Co. Overview
Table 44 : Merck & Co. Financial Analysis (USD Million)
Table 45 : Optovue Overview
Table 46 : Fresnel Prism & Lens Co. Overview

List of Figures

Fig 1: Global Thyroid Eye Disease Market Segmentation
Fig 2 : Global Thyroid Eye Disease Market: Healthcare Industry Value Chain
Fig 3: Image of Algorithm for investigating a patient with suspected Graves' hyperthyroidism
Fig 4: Porters Five Forces Analysis
Fig 5 : Global Thyroid Eye Disease Market Size, By Value (USD Million), 2017-2027
Fig 6 : Global Thyroid Eye Disease Market Share (%), By Diagnosis, By Value, 2017-2027
Fig 7: Global Thyroid Eye Disease Market Share (%), By Treatment, By Value, 2017-2027
Fig 8: Global Thyroid Eye Disease Market Share (%), By Region, By Value, 2017-2027
Fig 9 : North America Thyroid Eye Disease Market Size, By Value (USD Million), 2017-2027
Fig 10: North America Thyroid Eye Disease Market Share (%), By Diagnosis, By Value, 2017-2027
Fig 11: North America Thyroid Eye Disease Market Share (%), By Treatment, By Value, 2017-2027
Fig 12: North America Thyroid Eye Disease Market Share (%), By Country, By Value, 2017-2027
Fig 13 : Europe Thyroid Eye Disease Market Size, By Value (USD Million), 2017-2027
Fig 14: Europe Thyroid Eye Disease Market Share (%), By Diagnosis, By Value, 2017-2027
Fig 15: Europe Thyroid Eye Disease Market Share (%), By Treatment, By Value, 2017-2027
Fig 16: Europe Thyroid Eye Disease Market Share (%), By Country, By Value, 2017-2027
Fig 17 : The Asia-Pacific Thyroid Eye Disease Market Size, By Value (USD Million), 2017-2027
Fig 18: The Asia-Pacific Thyroid Eye Disease Market Share (%), By Diagnosis, By Value, 2017-2027
Fig 19: The Asia-Pacific Thyroid Eye Disease Market Share (%), By Treatment, By Value, 2017-2027
Fig 20: The Asia-Pacific Thyroid Eye Disease Market Share (%), By Country, By Value, 2017-2027
Fig 21 : Latin America Thyroid Eye Disease Market Size, By Value (USD Million), 2017-2027
Fig 22: Latin America Thyroid Eye Disease Market Share (%), By Diagnosis, By Value, 2017-2027
Fig 23: Latin America Thyroid Eye Disease Market Share (%), By Treatment, By Value, 2017-2027
Fig 24: Latin America Thyroid Eye Disease Market Share (%), By Country, By Value, 2017-2027
Fig 25 : the Middle East & Africa Thyroid Eye Disease Market Size, By Value (USD Million), 2017-2027
Fig 26: the Middle East & Africa Thyroid Eye Disease Market Share (%), By Diagnosis, By Value, 2017-2027
Fig 27: the Middle East & Africa Thyroid Eye Disease Market Share (%), By Treatment, By Value, 2017-2027
Fig 28: The Middle East & Africa Thyroid Eye Disease Market Share (%), By Country, By Value, 2017-2027
Fig 29: Global Thyroid Eye Disease Market: Company Analysis, By Value, 2020